Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8472723 | 0.85 | EPHX2 (0.64) | EPHX2KMT2AFABP7FABP5CASP3 | |
| SCHEMBL8366872 | 0.85 | EPHX2 (0.75) | EPHX2KMT2AMAPTFABP7FABP5 | |
| SCHEMBL694173 | 0.85 | EPHX2 (0.75) | EPHX2KMT2ALMNAMAPTMAPK1 | |
| SCHEMBL16977027 | 0.85 | EPHX2 (0.75) | EPHX2KMT2ALMNAMAPTMAPK1 | |
| SCHEMBL30089345 | 0.84 | EPHX2 (0.73) | EPHX2KMT2ALMNAMAPTMAPK1 | |
| SCHEMBL118921 | 0.84 | EPHX2 (0.73) | EPHX2KMT2ALMNAMAPTMAPK1 | |
| SCHEMBL29400630 | 0.84 | EPHX2 (0.73) | EPHX2KMT2ALMNAMAPTMAPK1 | |
| SCHEMBL2744086 | 0.84 | EPHX2 (0.73) | EPHX2KMT2ALMNAMAPTMAPK1 | |
| SCHEMBL2744944 | 0.82 | EPHX2 (0.72) | EPHX2KMT2ALMNAMAPTMAPK1 | |
| SCHEMBL30877549 | 0.82 | EPHX2 (0.72) | EPHX2KMT2AMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107935946-A | A kind of method for preparing Su Woleisheng intermediates | 上海科胜药物研发有限公司 | 2018-04-20 | — | — | CN | claimed |
| CN-107935946-A | A kind of method for preparing Su Woleisheng intermediates | 上海科胜药物研发有限公司 | 2018-04-20 | — | — | CN | disclosed |
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | EPHX2 3823/4885KMT2A 448/4885LMNA 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.